EyePoint, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EYPT Nasdaq 2830 eyepoint.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for EyePoint, Inc.

EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates - Aug 5th, 2026 7:00 am
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments - Aug 5th, 2026 5:00 am
Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says - Aug 4th, 2026 9:59 am
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates - Aug 4th, 2026 6:25 am
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) - Jul 30th, 2026 5:00 am
Earnings Preview: EyePoint (EYPT) Q2 Earnings Expected to Decline - Jul 29th, 2026 8:00 am
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jul 16th, 2026 5:00 am
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer - Jul 13th, 2026 5:00 am
Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks - Jul 6th, 2026 11:53 pm
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - May 26th, 2026 10:04 am
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - May 20th, 2026 11:13 pm
EyePoint Announces Participation at Upcoming Investor Conferences - May 19th, 2026 5:00 am
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - May 17th, 2026 12:33 pm
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More - May 17th, 2026 12:18 pm
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - May 17th, 2026 7:14 am
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - May 14th, 2026 5:00 am
EyePoint (EYPT) Q1 2026 Earnings Transcript - May 7th, 2026 9:51 am
EyePoint Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - May 7th, 2026 6:30 am
Eyepoint Pharmaceuticals Q1 Earnings Call Highlights - May 6th, 2026 9:54 am
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates - May 6th, 2026 6:25 am